Cargando…

1556. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in a self-pay population

BACKGROUND: Acute bacterial skin and skin structure infections (ABSSSI) are an increasing cause of admission in the self-pay population and can be difficult to treat due to socioeconomic status. We have previously described ABSSSI patients discharged to receive dalbavancin, a novel lipoglycopeptide,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray, E Yancey, Pizzuti, Adam G, Bland, Christopher M, Wagner, Jamie L, Gaul, Derek, Jones, Bruce M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777949/ http://dx.doi.org/10.1093/ofid/ofaa439.1736

Ejemplares similares

Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients
por: Pizzuti, Adam G., et al.
Publicado: (2020)

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
por: Jones, Bruce, et al.
Publicado: (2017)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
por: Giorgobiani, Manana, et al.
Publicado: (2022)

P1556: HYPER -FERRITINEMIA IN PEDIATRIC ONCOLOGY PATIENTS SECONDARY TO TREATMENT: DIAGNOSTIC APPROACH AND OUTCOME
por: Grafakos, I., et al.
Publicado: (2022)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
por: Freshwater, Dustin, et al.
Publicado: (2017)

Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
por: McCarthy, Matthew W., et al.
Publicado: (2019)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

Identification of M. tuberculosis Rv3441c and M. smegmatis MSMEG_1556 and Essentiality of M. smegmatis MSMEG_1556
por: Li, Shuang, et al.
Publicado: (2012)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

2370. Dalbavancin Use in Emergency Department and Observation Unit to Prevent Inpatient Admission for Acute Bacterial Skin and Skin Structure Infection (ABSSI)
por: Ford, Jonathan, et al.
Publicado: (2018)

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals
por: Bai, Francesca, et al.
Publicado: (2023)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
por: Bennett, Jason W, et al.
Publicado: (2008)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials
por: Riccobene, Todd, et al.
Publicado: (2023)

Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft-Tissue Infections
por: Burgess, Donna R, et al.
Publicado: (2017)

Escritores norteamericanos y británicos en México, 1556-1973
por: Gunn, Drewey Wayne, 1939-
Publicado: (1977)

Las claves de la Europa renacentista, 1453-1556
por: Pérez Samper, María Angeles

1556 Quality Improvement of Antiretroviral Therapy Errors at University Hospital
por: Shah, Jaimie, et al.
Publicado: (2014)

P1556: EVALUATION OF THE USEFULNESS OF INTERFERON-GAMMA RELEASE ASSAY FOR THE DETECTION OF LATENT MYCOBACTERIUM TUBERCULOSIS INFECTIONS IN PATIENTS WHO UNDERWENT HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Lee, Yoengjoon, et al.
Publicado: (2023)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
por: Stroffolini, Giacomo, et al.
Publicado: (2022)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Orígenes de la nacionalidad mexicana, 1521-1556 : la formación de una nueva sociedad
por: Liss, Peggy K.
Publicado: (1986)

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
por: Brescini, Lucia, et al.
Publicado: (2021)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin safety in the phase 2/3 clinical development program
por: Seltzer, E, et al.
Publicado: (2008)

1385. Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
por: Lovecchio, Frank, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tifcfsgpi436jiimt0fi4guhqk